AI IntelligenceSep 8, 2026AI Intelligence
Article
Insilico AI-designed drug reverses biological aging markers in trial
A Nature Biotechnology study indicates that rentosertib, an AI-designed drug by Insilico Medicine, may reverse biological aging markers. In a 42-patient trial, six independent aging clocks predicted treated patients were biologically up to six years younger than the placebo group.
Frontier EditorialSource: The Decoder
01
Source Brief
Insilico AI-designed drug reverses biological aging markers in trial: A Nature Biotechnology study indicates that rentosertib, an AI-designed drug by Insilico Medicine, may reverse biological aging markers. In a 42-patient trial, six independent aging clocks predicted treated patients were biologically up to six years younger than the placebo group.